Ceftriaxone Sodium

Necrotizing soft tissue infection (NSTI) caused by Haemophilus influenzae type B (Hib) is rare and life-threatening. We report severe monomicrobial Hib NSTI in a 16-month-old Inuit child who had received 3 doses of the Hib vaccine, highlighting vaccine failure and host susceptibility. The child sustained a minor fall to the left thigh without skin breakdown and developed fever the same day, initially treated with amoxicillin for presumed acute otitis media. He re-presented with persistent fever, progressive leg pain, swelling, ecchymosis, and refusal to weight-bear, prompting air transfer to the regional hospital and the initiation of ceftriaxone. Investigations showed C-reactive protein >90 mg/L, a white blood cell count of 13.6 ×10⁹/L, normal creatine kinase, and unremarkable radiographs. Owing to concern for necrotizing infection, the patient was transferred to a tertiary pediatric intensive care unit. Antimicrobials were escalated to piperacillin-tazobactam, vancomycin, and clindamycin, and intravenous immunoglobulin was administered. Emergent surgical debridement demonstrated extensive dermal and subcutaneous necrosis with preserved fascia and muscle. Blood and tissue cultures grew Hib. He required mechanical ventilation, inotropic support, and multiple additional debridements prior to skin grafting. Household contacts received chemoprophylaxis. Immunologic evaluation was unremarkable; genetic testing was non-diagnostic. NSTI requires prompt recognition, surgical debridement, and targeted antimicrobial therapy. While most cases are due to group A Streptococcus or polymicrobial infections, Hib is rare, with few pediatric cases reported. Vaccine failures occur, particularly before the 18-month booster, reflecting waning immunity. Indigenous populations remain disproportionately affected. Invasive Hib disease despite vaccination warrants evaluation for underlying immunodeficiency. Invasive Hib infection should be considered even in fully vaccinated children. Continued surveillance, prompt surgical management, public health response and investigations of host susceptibility remain essential.

Bloodstream infections (BSIs) by methicillin-susceptible Staphylococcus aureus (MSSA) are a significant cause of morbidity and mortality, traditionally treated with antistaphylococcal penicillins (ASPs) or cefazolin. Ceftriaxone has emerged as an alternative due to its once-daily dosing regimen and favourable safety profile; however, its efficacy compared to the standard of care (SoC) remains controversial. This evidence synthesis aimed to assess the role of ceftriaxone in treating MSSA-BSIs.

A systematic literature search was conducted in PubMed, Embase, and Scopus up to December 31, 2025 (PROSPERO protocol CRD42024595748). Studies comparing ceftriaxone to ASPs or cefazolin for MSSA-BSIs were included. Primary outcomes were 30-day and 90-day all-cause mortality . Pooled effect sizes with their 95% confidence intervals (CIs), were calculated using random-effects models, odds ratios (ORs) and mean differences (MDs) according to the type of outcome.

Eleven studies totalling 2,568 patients were included. Ceftriaxone was associated with significantly increased 30-day mortality (OR 3.33; 95% CI: 2.17-5.10), although differences at 90 days were not significant (OR 1.71; 95% CI: 0.75-3.90). No significant differences were noted for clinical success (OR 0.49; 95% CI: 0.19-1.26), microbiological clearance (OR 1.66; 95% CI: 0.73-3.82). Adverse event rates were similar between groups.

Given the availability of various alternatives and the consistent short-term mortality signal observed, routine use of ceftriaxone for MSSA-BSIs, especially as initial therapy, is not supported by current evidence. Only novel findings from randomized studies may change the place in therapy of the drug in this context.